A study finds that nearly 19 percent of people with mental illnesses use prescription drugs, while only 5 percent of other people do.
Documents examined by Kaiser Health News shed light on the workings of the Trump administration’s “Drug Pricing and Innovation Working Group.”
This year’s American Diabetes Association scientific meeting came with a hefty price — a policy of no photography and limits on social media. That did not go over well on Twitter.
Due to poor doctor-patient communication, most people with advanced cancer don’t know enough about their disease to make vital decisions.
One insurer is turning the tables on drugmakers with what may be a new job category: a sales force for cost-effective medicine.
With the cost of medications up 300 percent in the past decade, supporters see this as a first step to rein in prices.
One in 9 Medicare enrollees have COPD and many of them can’t afford the inhalers that keep them out of the emergency room.
A new JAMA study examines how drug rebates can direct money to middlemen and force Medicare patients to cough up more money.
A new law gives Medicaid regulators power to threaten drugmakers with cost-effectiveness scrutiny unless they grant additional rebates.
Una nueva investigación ha vinculado a los PPI, con graves efectos secundarios, incluyendo enfermedad renal crónica, y demandas presentadas recientemente alegan que los que producen la droga deberían haber sabido sobre sus daños potenciales.
With flawed systems for tracking the side effects of prescription drugs, a link between proton pump inhibitors and kidney disease suggested by research cannot be proven. Patients who swear by the drugs hope it won’t be.
Even the most exalted among us realize health care policy is complicated. Here’s a pop quiz to see what you have learned as a regular reader of Kaiser Health News.
A look at how and why strategic, star-studded advertising brought a drug for a little-known neurological condition into your home.
More than 70 drugs approved from 2001 through 2010 ran into safety concerns later that resulted in withdrawals from the market, “black box” warnings or other actions.
¿Qué hacer si el plan del Medicare no autoriza el suministro de un medicamento? Pasos a seguir para conseguirla.
Several public health officials endorse using a federal law to slash hepatitis C drug prices in Louisiana and avoid drug bills that could cripple the state budget.
Senior citizens have to be patient and keep close records to appeal when Medicare plans refuse to cover their medicines.
La dura posición del gobierno de Trump sobre inmigración podría estimular recortes en la financiación federal y complicar una amplia variedad de programas de salud en estas ciudades.
Local health officials are bracing for the potential impact of a Trump administration policy that would stop federal funding to jurisdictions that don’t enforce federal immigration laws.
A California lawmaker wants to strengthen collaboration among public agencies to bring down costs to taxpayers.